Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML

This study is testing a combination treatment for people newly diagnosed with a type of blood cancer called acute myeloid leukemia (AML). The treatment combines a drug called venetoclax with a technique called microtransplant, where donor stem cells are used to help the immune system fight the cancer — without a full stem cell transplant. **You may be eligible if...** - You are 18 or older and have been newly diagnosed with AML - You have not received prior treatment for leukemia (except hydroxyurea or a blood-filtering procedure) - Your heart, liver, and kidneys are functioning well enough for treatment - You have a willing donor (at least 18 years old) who partially matches your immune system **You may NOT be eligible if...** - You have a specific subtype of leukemia called acute promyelocytic leukemia, or certain other related conditions - You have an uncontrolled infection or active bleeding - You have serious heart disease, an uncontrolled autoimmune condition, or a severe psychiatric disorder - You are pregnant, breastfeeding, or not willing to use contraception - You have had major surgery in the past 4 weeks Talk to your doctor to see if this trial is right for you.